Fulltext present in this item

Thumbnail
Fulltext: 220218.pdf
Format: PDF
Description: publisher's version
Title: Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report.
Author(s): Meijer, E.F.J.; Dofferhoff, A.S.M. ; Hoiting, O.; Buil, J.B. ; Meis, J.F.
Publication year: 2020
Source: Journal of Fungi, vol. 6, iss. 2, (2020), article E79
ISSN: 2309-608X
DOI: https://doi.org/10.3390/jof6020079
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/220218   https://hdl.handle.net/2066/220218

Display more details
Subject: Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences
Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences
Organization: Internal Medicine
Medical Microbiology
Journal title:
Journal of Fungi
Volume: vol. 6
Issue: iss. 2
Article number: E79
Abstract:
COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agents puts emphasis on early surveillance for azole-resistant Aspergillus species. We present a patient with putative CAPA due to Aspergillus fumigatus with identification of a triazole-resistant isolate during therapy. We underline the challenges faced in the management of these cases, the importance of early diagnosis and need for surveillance given the emergence of triazole resistance.

This item appears in the following Collection(s)

Browse

Statistics